NCT06305000
Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis
At risk: Primary completion moved 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Primary completion pushed from Sep 10, 2026 to Dec 10, 2026
- Study completion pushed from Sep 10, 2026 to Jan 10, 2027
- Secondary endpoints: details revised at 19 of 20 entries
- Notable Primary and study completion dates: Sep 10, 2025 to Sep 10, 2026
- Enrollment target: 64 to 48
- Study arms: 4 to 3
- Notable Primary and study completion dates pushed to Sep 10, 2025v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Minor Start date: Mar 10, 2024 to Mar 27, 2024v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Inflammatory parameter levels in peri-implant crevicular fluid
Timeframe: Baseline (prior to therapy)
Secondary (5)
Plaque index (Silness & Löe, 1964)
Gingival Index ( Löe & Silness,1963)
Bleeding on probing (Ainamo & Bay 1975)
Keratinized mucosa width
Probing depth
Arms and interventions
Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm)No intervention
Peri-implant mucositis group with sufficient keratinized mucosa (≥ 2mm)Experimental
Only non-surgical therapy will apply
Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm) receiving FGGExperimental
Free gingival graft will apply following non-surgical therapy
Procedures: Non-surgical treatment, Free gingival graft
Sites
1 site in 1 country
- Biruni UniversityIstanbul, Turkey (Türkiye)